Clinical Trial Update: First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 [Phase 1]

View source ↗

Summary

Phase 1 first-in-human dose escalation and expansion study of BYON4228, a SIRPα-directed monoclonal antibody, in lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• BYON4228

Snippet

Sponsor: Byondis B.V. | Conditions: Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING